The GW Pharma and Parallel Transactions: Where Does the Future of Cannabis go From Here?
This month, two groundbreaking deals in cannabis were announced — the acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals and the combination of the multi-state operator (MSO) Parallel with the special purpose acquisition company (SPAC), Ceres Acquisition Corp. The proximity of two such large deals in one month begs the question: Are the GW Pharma — Jazz and Ceres — Parallel deals an important barometer to the direction of cannabis, both in North America and abroad? In His Genes The biopharma influence on the cannabis sector started early with the drive toward adoption of curr...